Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (amn) Study

Jae Hoon Lee,Kihyun Kim,Jin Seok Kim,Chang Ki Min,Sung-Soo Yoon,Kazuyuki Shimizu,Takaaki Chou,Hiroshi Kosugi,Kenshi Suzuki,Hiroyuki Hata,Wenming Chen,Jian Hou,Jin Lu,Shang-Yi Huang,Wee-Joo Chng,Daryl Tan,Gerrard Teoh,James Chor Sang Chim,Noppadol Siritanaratkul,Weerasak Nawarawong,Brian G. M. Durie
DOI: https://doi.org/10.1002/ajh.23731
IF: 45.3
2012-01-01
Journal of Clinical Oncology
Abstract:8097 Background: The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However the difference of clinical characteristics between ethnic groups is not well-defined. In Asian countries the incidence of MM has been lower compared with Western countries. However, there are growing evidences that MM is increasing very rapidly in this region. Until now, only few data of Asian patients has been reported. Asian myeloma network (AMN) decided to analyze the first multinational project to explore clinical characteristics of Asian MM patients and clinical practice performed in Asian countries. Methods: Data were collected from 21 centers from 7 countries and regions were collected retrospectively. Clinical characteristics of 2969 symptomatic MM patients at diagnosis were described. Overall survival (OS) and prognostic factors were analyzed for 2273 patients who have survival data. Results: Median OS was 54 months (95% CI 48.0-60.0). Patients who were diagnosed before 2000 were shorter survival. Transplantation was performed to 513 patients with better survival (84 vs. 45 months, p<0.001). First line treatment of 2339 evaluable patients was analyzed. Overall response rate was 71% with 30%, VGPR or better. New drugs including bortezomib, thalidomide or lenalidomide were combined for 32.5% of all 2339 patients without difference in response rate or OS according to combination. Conclusions: We successfully described clinical characteristics of Asian MM patients and this project will be the base for future studies or clinical trials for Asian MM patients. Updated analyses and comparison with Western data will be presented. AMN, supported by the International Myeloma Foundation (IMF) IMWG initiative.
What problem does this paper attempt to address?